Strategic Marburg Advanced Research and Development, Preparedness, Registration, Evaluation and Procurement (SMART-PREP)
Health and Human Services (all) · BARDA - ASPR / DAAPPO / BARDA DCMA
No listed company matched (Materiality N/A)
Capture briefs (a one-page, shareable copy of this page) are part of Pro. The CSV here holds the notice, its timeline and past awards.
Where this opportunity stands
Every notice posted under solicitation 75A50126C00001 in this department, oldest first.
- May 7, 2026 · this noticeAward NoticeALBERT B. SABIN VACCINE INSTITUTE, INC. · $1.0B
Next steps for this stage
Standard steps for the notice type; not advice about this buyer.
- Note the winner and the end of the period of performance for the recompete.
- Follow the agency to see the next notice for this work.
What the notice says
This acquisition will allow BARDA to invest Project BioShield funds for the advanced development, US Food and Drug Administration (FDA) licensure, procurement, shipping, and vendor managed inventory (VMI) storage of MARV monovalent vaccine. This contract was awarded on a hybrid cost reiumbursement/fixed price basis as circumstances do not allow the agency to define its requirements sufficiently to allow for a fixed-price type contract.
Who won similar work
8 award notices on SAM.gov in the last 24 months. Matched by: Same office (BARDA - ASPR / DAAPPO / BARDA DCMA), same NAICS 541714.
Single-winner award sizes (8): middle half $75.8M to $232.4M, median $142.9M; range $84K to $340.9M.
| Winner | Awards | Value | Last |
|---|---|---|---|
| KALEO, INC. | 1 | $340.9M | Sep 30, 2026 |
| CIDARA THERAPEUTICS INC | 1 | $339.2M | Oct 14, 2025 |
| VERICEL CORPORATION · $VCEL · $197.5M | 1 | $196.9M | Apr 2, 2026 |
| RAFA LABORATORIES LTD | 1 | $186.0M | Oct 1, 2025 |
| Flosonics Medical LLC | 1 | $99.7M | Jun 5, 2026 |
| OSIVAX Paris 8 �le-de-France 75008 FRA | 1 | $98.6M | Oct 14, 2025 |
| ISOLA THERAPEUTICS INC | 1 | $7.5M | Apr 27, 2026 |
| MEDIMMUNE LLC | 1 | $84K | Mar 17, 2025 |
Value counts single-winner awards. "Shared" awards are multiple-award contracts that list every winner with the same total ceiling; that ceiling is not one company's win, so it is not added in. Revenue next to a ticker is the company's last annual revenue from its 10-K.
- $VCEL reported $197.5M revenue in FY2025. The median single-winner award in these 8 past awards, $142.9M, is 72% of that. 10-K
One award's total value against one year of revenue; many awards are paid over several years.
- Sep 30, 2026KALEO, INC.$340.9MRFP - 2-PAM Autoinjectors for Project Bioshield (PBS)No listed company matched (Materiality N/A)
- Jun 5, 2026Flosonics Medical LLC$99.7MBiomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA)No listed company matched (Materiality N/A)
- Apr 27, 2026ISOLA THERAPEUTICS INC$7.5MBARDA DRIVe EZ-BAA (EZBAA - 22-100-SOL-00003)No listed company matched (Materiality N/A)
- Apr 2, 2026VERICEL CORPORATION$196.9MNonSurgical DebridementMateriality: 99.7% of $VCEL revenue (High) SEC
- Oct 14, 2025OSIVAX Paris 8 �le-de-France 75008 FRA$98.6MClinical Proof of Concept of OVX836, a single-shot broadly protective Influenza A vaccine for immediate protection against emerging pandemic strainsNo listed company matched (Materiality N/A)
- Oct 14, 2025CIDARA THERAPEUTICS INC$339.2MDevelopment of CD388 as a long-lasting prophylactic anti-viral option for protection against the health impacts caused by influenzaNo listed company matched (Materiality N/A)
- Oct 1, 2025RAFA LABORATORIES LTD$186.0MDevelopment Of a Concentrated Tranexamic Acid (TXA) Intramuscular InjectionNo listed company matched (Materiality N/A)
- Mar 17, 2025MEDIMMUNE LLC$84KProcurement of storage and stability services to maintain BARDA�s supply of Live Attenuated Influenza Virus Master and Working Seed LotsNo listed company matched (Materiality N/A)
Materiality: one award's value as a share of the winner's revenue over the latest 12 months in its SEC filings (or its last fiscal year, as noted when you point at it). Low under 1%, Medium 1 to 5%, High 5% or more. Many awards are paid over several years, so this overstates a single year's share.
Competitive landscape
For the 8 most frequent past winners above. Lobbying is matched by the company's exact name or exact ticker; agencies are as named on the filings.
- 2 of these past winners lobbied Health & Human Services, Dept of (HHS) since 2024 (7 filings)
- 2 of their lobbyists list a past Health & Human Services, Dept of (HHS) job
- No corporate PAC money from them to the overseeing committees since 2024
- 0 foreign-agent (FARA) registrations
Policy around it
Bills the past winners named while lobbying this agency's issues, rules from the department, and executive orders that name the agency, last 12 months.
- 0 bills named on the past winners' lobbying filings
- 252 rules from the department in the last 12 months
- 0 executive orders naming the agency in the last 12 months
Market
For past winners matched exactly to a listed company. Insider trades are open-market buys and sells (Form 4) in the last 90 days, shown as facts; our own study found insiders do not reliably buy ahead of awards. A sale marked 10b5-1 was made under a trading plan set up in advance.
- 1 of the past winners are listed companies
- 0 insider buys and 0 insider sells at them in the last 90 days
Sources: SAM.gov notices and award notices; Senate LDA lobbying filings; FEC filings; FARA; Federal Register; congress.gov; SEC Form 4. Every row above links to its record.
Companies are matched to tickers by exact name only. A company we could not match shows no market rows; that is a miss, not a finding.